Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
� Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT �
To access the conference call, please register using this . Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto and proceed to the Event Calendar page under the Investors & News heading. A webcast replay of the conference call will also be archived on for one year.
About Exelixis
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit , follow on X (Twitter), like on Facebook and follow on LinkedIn.
Exelixis, the Exelixis logo and CABOMETYX are registered
View source version on businesswire.com:
Investors Contact:
Varant Shirvanian
Director, Investor Relations
Exelixis, Inc.
650-837-7917
[email protected]
Media Contact:
Hal Mackins
For Exelixis, Inc.
415-994-0040
[email protected]
Source: Exelixis, Inc.
